摘要
癌肉瘤又稱爲惡性混合中胚層瘤、類肉瘤癌、或惡性混合繆勒氏瘤，乃一種高度惡性腫瘤，佔所有惡性卵巢腫瘤之2%不到。治療主要先行減積手術，然後追加輔助性化學治療。由於此腫瘤息者很少，尚沒有統一的標準化療藥物。一般認爲platinum較有效，最近研究，認爲使用platinum，再加上ifosfamide或taxane更佳。
並列摘要
Ovarian carcinosarcoma, also termed malignant mixed mesodermal tumors (MMMTs), sarcomatoid carcinoma, or malignant mixed mullerian tumors are highly virulent, and comprise less than 2% of ovarian malignancies. These patients are recommended to treat with debulking surgery followed by adjuvant chemotherapy. No definitive conclusion regarding postoperative therapy can be drawn because of the rarity of the lesion and the small number of patients undergoing a particular therapy. Several studies have suggested that platinum compounds have activity in this disease. In addition, according several recent report, the use of combination of platinum with ifosfamide or taxane seem to be effective treatment for patients with ovarian carcinosarcoma.
延伸閱讀
- 陳韻元（2022）。卵巢癌。聲洋防癌之聲，(172)，2-9。https://www.airitilibrary.com/Article/Detail?DocID=a0000043-N202303250001-00001
- 顏兆熊、余慕賢（2007）。卵巢癌。當代醫學，(403)，361-366。https://doi.org/10.29941/MT.200705.0004
- 林從慶（1989）。卵巢腺癌。當代醫學，(191)，770-772。https://doi.org/10.29941/MT.198909.0013
- 李耀泰、陳福民、郭宗正（2022）。Ovarian cancer complicated pregnancy。婦癌醫學期刊，(55)，29-32。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-202204-202204290007-202204290007-29-32
- Ling, K. S., Chen, G. D., Tsai, H. J., Lee, M. S., Wang, P. H., & Liu, F. S. (2005). Genetic Changes in Ovarian Cancer. Taiwanese Journal of Obstetrics & Gynecology, 44(3), 218-231. https://doi.org/10.29787/TJOG.200509.0003